KM Research Hub
← 返回结果库查看论文详情PubMed ↗
READ-ONLY DIGITIZATION RESULT

First-Line Tislelizumab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Cancer: Three-Year Follow-Up of the Phase 3 RATIONALE-309 Randomized Clinical Trial.

JAMA Oncol · 2026-Apr-01 · PMID 41746630

Panel Figure_3提取完成待 EXE 对齐验证

Overall Survival (OS)

Figure 3.. Overall Survival (OS) in the Intent-to-Treat Analysis Set The data cutoff was December 8, 2023. In the tislelizumab plus chemotherapy arm, there were 55 OS events (42.0%) over a median of 45.3 months (95% CI, 33.4 to not estimable); in the placebo plus chemotherapy arm, there were 64 OS events (48.5%) over a median of 31.8 months (95% CI, 25.0 to not estimable) (hazard ratio, 0.73; 95% CI, 0.51-1.05). The hazard ratio was estimated from a stratified Cox model with the placebo plus chemotherapy arm as a reference group. In the tislelizumab plus chemotherapy arm, the 12-month, 24-month, and 36-month OS rate was 89.6% (95% CI, 82.8-93.8), 69.4% (95% CI, 60.4-76.8), and 55.6% (95% CI, 46.0-64.1), respectively; in the placebo plus chemotherapy arm, the 12-month, 24-month, and 36-month OS rate was 84.9% (95% CI, 77.1-90.2), 59.6% (95% CI, 50.1-67.9), and 46.4% (95% CI, 36.9-55.3), respectively. Circles represent censored participants.

算法:legacy-0.5.0引擎:enhanced-linux
质量评分1.00
质量通过是
预期曲线2
实际曲线2
X 范围-
Y 范围-

曲线数据

网页最多预览 200 行,完整数据请下载 CSV 或 JSON。

当前面板没有可预览的 `curves_mapped.csv` 数据。
历史版本(1)

重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。

版本状态验证曲线时间
legacy-0.5.0complete待验证22026-07-18T19:13:02+00:00